Trials / Completed
CompletedNCT02581644
Assessment of Effectiveness of Belatacept Patient Alert Card in Patients Following Renal Transplantation in a Sample of EU Countries
Evaluation of the Effectiveness of the Belatacept (Nulojix®) Patient Alert Cards in Patients Following Renal Transplantation in European Economic Area Countries
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 63 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine a) if the implementation of belatacept patient alert card (PAC) resulted in effective understanding of key safety messages and b) if the degree of understanding of key safety messages is associated with improved clinical and safety outcomes.
Detailed description
3 sub studies: 2 Cross-Sectional and 1 retrospective chart review
Conditions
Timeline
- Start date
- 2016-11-29
- Primary completion
- 2017-05-19
- Completion
- 2017-05-19
- First posted
- 2015-10-21
- Last updated
- 2017-06-16
Locations
14 sites across 4 countries: Austria, France, Germany, Sweden
Source: ClinicalTrials.gov record NCT02581644. Inclusion in this directory is not an endorsement.